Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Documenti analoghi

• Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
  di: Yiu, Z.Z.N., et al.
  Pubblicazione: (2018)
• Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
  di: Iskandar, Ireny Y.K., et al.
  Pubblicazione: (2018)
• Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
  di: Yiu, Zenas Z. N., et al.
  Pubblicazione: (2020)
• Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
  di: Mahil, S.K., et al.
  Pubblicazione: (2019)
• Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
  di: Yiu, Zenas Z.N., et al.
  Pubblicazione: (2016)